Insulet Corporation (PODD) FY2025 Earnings Quality Report

Grade: B — Generally healthy, minor concerns

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Grant Thornton LLP — Unqualified opinion (1 critical audit matter: Provision for rebates)

One-line verdict: Insulet earns a B grade — the only non-F in this medical-device cohort. Zero fail flags, two watch items (CapEx growth outpacing revenue and cash covering 75% of debt), and a clean M-Score of -2.57. Revenue grew 30.7% in FY2025 to $2.7B, driven by Omnipod 5 penetration in the U.S. and international launches across 13 additional countries. Operating cash flow of $569M represents a 2.3x multiple over net income, reflecting significant non-cash items from the $123.9M debt extinguishment loss. The business is scaling rapidly with minimal accounting concerns — the main items to monitor are the receivables spike (+43.7% vs. 30.7% revenue growth) and a $541.5M cash outflow to repurchase Convertible Senior Notes.

The Omnipod Franchise

Insulet describes its mission in the MD&A: "Our mission is to transform the lives of people with diabetes. We are primarily engaged in the development, manufacture, and sale of our proprietary Omnipod product platform, a continuous insulin delivery system for people with insulin-dependent diabetes."

The company explicitly warns of product concentration in Item 1A: "We currently rely on sales of our Omnipod product platform to generate most of our revenue. We expect to continue to derive nearly all our revenue from our Omnipod product platform."

The FY2025 revenue breakdown from the MD&A:

International growth of 44.1% is being driven by the multi-country Omnipod 5 rollout. From the MD&A: "In 2025, we launched Omnipod 5 in nine additional countries... Following the launch of Omnipod 5 in several countries in the Middle East in early 2026, Omnipod 5 is now available in 19 countries."

The U.S. customer base reached "more than 600,000 estimated active Omnipod users globally" as of December 31, 2025.

The Drug Delivery segment — where Insulet supplies a customized Pod to Amgen for Neulasta Onpro — is in managed decline, as the 10-K warns in Item 1A: "Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen's Neulasta Onpro kit under an agreement that expires in December 2028."

(1) FY2024 net income was inflated by a $118.1M income tax benefit from releasing a deferred tax asset valuation allowance.

The apparent "net income decline" from $418.3M (2024) to $247.1M (2025) is optics, not operational weakness. Operating income actually grew from $308.9M to $473.8M — a 53% increase. The 2025 GAAP net income was compressed by (a) a $123.9M loss on debt extinguishment (the buyback of Convertible Senior Notes), and (b) a $92.4M tax provision in 2025 compared to a $118.1M tax benefit in 2024. On an operating basis the business accelerated meaningfully.

Cash Flow: Strong Operating Generation

Operating cash flow of $569.3M grew 32% YoY, roughly matching revenue growth. The 2.30x CFFO/NI ratio is inflated by the non-cash $123.9M debt extinguishment loss (added back) and other working capital items. Even adjusting for those, underlying cash conversion is healthy.

The $219.4M of CapEx in 2025 is +63.7% YoY — the engine's B2 watch flag. This reflects the build-out of two new manufacturing plants. From the MD&A: "We began producing product at our new manufacturing plant in Malaysia in 2024 and are already investing in another manufacturing plant in Costa Rica to support our continued growth." For a company that needs to scale Pod production in line with 30%+ unit volume growth, building physical capacity in advance of demand is the correct strategic move.

The Balance Sheet: Transformed by Debt Refinancing

Total debt fell from $1.38B to $949M — a $431M reduction — driven by the Convertible Senior Notes repurchase. From the MD&A: "During 2025, we repurchased $419.9 million in principal ($417.6 million net of issuance costs) of our Convertible Senior Notes for $541.5 million in cash, which resulted in a $123.9 million loss on extinguishment."

Cash fell from $953M to $716M because of that repurchase. The net balance sheet picture: cash of $716M covers 75% of the reduced $949M debt load (C4 watch, not fail). Net debt is a manageable $233M.

The 18-Point Screening

Revenue Quality

A2: AR grew 43.7% vs. revenue growth of 30.7%. The engine passes this because the absolute growth rates are both healthy and AR is not outpacing revenue by more than 1.5x. The DSO increase of 6 days is within acceptable band. Note that the balance sheet reports $516.9M total AR in FY2025 vs. $252.5M + $113.0M related party AR in FY2024 — the comparison is cleaner than the top-line number suggests because the related-party AR is being reclassified.

From the MD&A, U.S. revenue growth was partly driven by "higher sales volume driven by growing our customer base. Revenue from the sale of Omnipod products in the U.S. includes $511.6 million of related party revenue in 2025, compared with $587.8 million in 2024." The related-party channel is being reduced in favor of the pharmacy channel — a positive transparency signal.

Expense Quality

B2 (watch): CapEx grew from $134.0M to $219.4M — +63.7%. The MD&A attributes this to the Malaysia and Costa Rica manufacturing capacity builds. For a device business with 600k+ active users generating recurring pod reorders every 3 days, this is capacity investment ahead of demand.

B4: Gross margin expanded from 69.8% to 71.6%. Per the MD&A: "The 180 basis points increase in gross margin was primarily driven by improved manufacturing and supply chain efficiencies, a higher average selling price, increased volume and a $13.5 million charge in the prior year related to certain components utilized in OmnipodGO." Omnipod GO was cancelled in favor of pushing Omnipod 5 into the type 2 market.

Cash Flow Quality

C4 (watch): Cash of $716.1M covers 75% of the $949.2M debt. This is not a fail (fails are at <30%), but the ratio declined from effectively 69% last year to 75% this year — actually improved, because debt fell faster than cash. The cash drop from $953M to $716M was a deliberate capital allocation choice (retire expensive convertibles), not operational weakness.

The C3 accruals ratio of -10.1% is excellent — cash flow is 10% higher than accrual earnings would imply, the opposite of a manipulation signal.

Balance Sheet

Insulet's balance sheet is organically built — goodwill of $51.6M and intangibles of $117.1M total just 11% of equity. This is rare for a medical device company and reflects the fact that Omnipod was developed in-house, not acquired.

M&A Risk

Beneish M-Score

M-Score of -2.57 is comfortably below the -2.22 threshold. Gross margin expansion and strong cash conversion both contribute to the clean result.

Critical Audit Matter: Rebate Provisions

Grant Thornton identified one critical audit matter — the provision for rebates. From the audit report: "As described further in note 2 to the consolidated financial statements, the Company provides for certain rebates for sales of its product through intermediaries. The Company estimates variable consideration related to rebates to managed care organizations, including pharmacy benefit managers, governmental payors, and third-party commercial payors, primarily in the United States when determining the transaction price at the time of sale."

GT explained its reasoning: "The principal consideration for our determination that the provision for rebates is a critical audit matter is the high degree of auditor judgment in applying procedures to evaluate the significant estimation made by management. Management's estimate is based on historical experience, sales, trends, levels of inventory in the distribution channel, and contractual terms."

Procedures performed included: "Evaluated the significant assumptions and the completeness and accuracy of the underlying data used in management's calculation through inspection of source documents and agreement to other audited schedules. Performed retrospective analysis comparing actual rebates incurred to the previously estimated amounts. Tested the design and operating effectiveness of controls related to management's estimate."

Rebate accounting is the standard area of auditor focus for pharmaceutical and diabetes product companies because of the complex chain of PBM and managed care contract terms. GT has served as Insulet's auditor since 2016.

Key Risks from Item 1A

1. Single-product concentration. From Item 1A: "We currently rely on sales of our Omnipod product platform to generate most of our revenue. We expect to continue to derive nearly all our revenue from our Omnipod product platform."

2. Customer retention. From Item 1A: "A key to driving our revenue growth is the retention of a high percentage of our customers. If demand for our products decreases as a result of economic conditions, competition, perceived inadequate customer service, product performance issues or otherwise, our ability to retain customers could be harmed."

3. Competitive pressure from GLP-1s and new pumps. From Item 1A: "Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable... Further, increased availability and adoption of the GLP-1 class of drugs may delay the progression of type 2 diabetes in obese patients." Competitors include Medtronic Diabetes (which "is being spun out into a new, independent publicly traded company"), Tandem Diabetes Care, and Beta Bionics.

4. Reimbursement risk. From Item 1A: "sales of our Omnipod products would be limited if a substantial portion of their sales price is not paid for by third-party payors... contracts... can generally be terminated by the third-party payor without cause."

5. Drug Delivery wind-down. From Item 1A: "Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen's Neulasta Onpro kit under an agreement that expires in December 2028." Management will need to either renew or replace this revenue stream by 2029.

6. Tariff exposure. From the MD&A: "While we do not expect tariffs to have a significant impact on our gross margin in 2026, should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years."

Altman Z-Score and F-Score

Z-Score of 4.62 is comfortably in safe territory. The F-Score of 1.14 is consistent with a clean, growing mid-cap medical device business.

Summary

Grade: B. Clean bill of health with two watch items.

Insulet is the cleanest company in this medical device cohort. Zero fail flags, zero critical audit concerns beyond standard rebate estimation, strong organic balance sheet (goodwill only 11% of equity vs. 90%+ for the serial acquirers in this peer group), and a growing business (+30.7% revenue). The apparent headline net income decline ($418M → $247M) was entirely from a $123.9M debt extinguishment loss plus a one-time FY2024 tax benefit that did not repeat — operating income actually grew 53%.

The two watch items are both defensible:

The real business risks are single-product concentration, customer retention in an increasingly competitive diabetes device market, and the expiration of the Amgen Drug Delivery contract at the end of 2028. The accounting supports a clean bill of health; the strategic risks are standard medtech.

**Disclaimer**: This report is based on Insulet Corporation's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Grant Thornton LLP (Unqualified opinion, 1 critical audit matter: Provision for rebates)